Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Viktrup

Showing results (71-80 of 111) with videos related to

Pageof 12
Sort By:
BJU International|January 20, 2011
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyCraig F Donatucci, Gerald B Brock, Evan R Goldfischer, et al.
Patient Preference and Adherence|March 6, 2025
Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims StudyOralee J Varnado, Michelle Vu, Erin K Buysman, et al.
The Journal of Headache and Pain|December 18, 2024
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody preventionChristian Lampl, Elizabeth Seng, Maurice Vincent, et al.
Journal of Clinical Medicine|January 21, 2023
Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic SurgeonsThomas J Schnitzer, Rebecca L Robinson, Lars Viktrup, et al.
Current Medical Research and Opinion|August 18, 2022
Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trialsPhilip Mease, Louis Kuritzky, Wendy L Wright, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 27, 2018
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled studyZhichao Zhang, Hanzhong Li, Xiaodong Zhang, et al.
Pain and Therapy|September 19, 2024
Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)Elizabeth Seng, Christian Lampl, Lars Viktrup, et al.
The Journal of Rheumatology|March 2, 2022
WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or KneePhilip G Conaghan, Robert H Dworkin, Thomas J Schnitzer, et al.
Postgraduate Medicine|November 2, 2020
Pain severity and healthcare resource utilization in patients with osteoarthritis in the United StatesSri Nalamachu, Rebecca L Robinson, Lars Viktrup, et al.
Pain Practice : the Official Journal of World Institute of Pain|November 15, 2021
Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countriesSerge Perrot, Michael J Doane, Dena H Jaffe, et al.
Pageof 12

Showing results (71-80 of 111) with videos related to

Sort By:
Pageof 12
BJU International|January 20, 2011
Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension studyCraig F Donatucci, Gerald B Brock, Evan R Goldfischer, et al.
Patient Preference and Adherence|March 6, 2025
Treatment Patterns and Healthcare Resource Utilization by Gender and Migraine Frequency in Adult Patients Receiving Galcanezumab Versus Standard of Care Preventive Medications Over 24 months: A United States Retrospective Claims StudyOralee J Varnado, Michelle Vu, Erin K Buysman, et al.
The Journal of Headache and Pain|December 18, 2024
Interictal burden in migraine patients at the outset of CGRP monoclonal antibody preventionChristian Lampl, Elizabeth Seng, Maurice Vincent, et al.
Journal of Clinical Medicine|January 21, 2023
Opioid Prescribing for Osteoarthritis: Cross-Sectional Survey among Primary Care Physicians, Rheumatologists, and Orthopaedic SurgeonsThomas J Schnitzer, Rebecca L Robinson, Lars Viktrup, et al.
Current Medical Research and Opinion|August 18, 2022
Efficacy and safety of tanezumab, NSAIDs, and placebo in patients with moderate to severe hip or knee osteoarthritis and a history of depression, anxiety, or insomnia: post-hoc analysis of phase 3 trialsPhilip Mease, Louis Kuritzky, Wendy L Wright, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|October 27, 2018
Efficacy and safety of tadalafil 5 mg once-daily in Asian men with both lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: A phase 3, randomized, double-blind, parallel, placebo- and tamsulosin-controlled studyZhichao Zhang, Hanzhong Li, Xiaodong Zhang, et al.
Pain and Therapy|September 19, 2024
Patients' Experiences During the Long Journey Before Initiating Migraine Prevention with a Calcitonin Gene-Related Peptide (CGRP) Monoclonal Antibody (mAb)Elizabeth Seng, Christian Lampl, Lars Viktrup, et al.
The Journal of Rheumatology|March 2, 2022
WOMAC Meaningful Within-patient Change: Results From 3 Studies of Tanezumab in Patients With Moderate-to-severe Osteoarthritis of the Hip or KneePhilip G Conaghan, Robert H Dworkin, Thomas J Schnitzer, et al.
Postgraduate Medicine|November 2, 2020
Pain severity and healthcare resource utilization in patients with osteoarthritis in the United StatesSri Nalamachu, Rebecca L Robinson, Lars Viktrup, et al.
Pain Practice : the Official Journal of World Institute of Pain|November 15, 2021
Burden of chronic low back pain: Association with pain severity and prescription medication use in five large European countriesSerge Perrot, Michael J Doane, Dena H Jaffe, et al.
Pageof 12